IAG933 in solid tumors incl. EHE

 

Trial name: IAG933 in Advanced Solid Tumors incl. EHE
Agents: IAG933
Phase I
Status Recruiting
Sponsor Novartis Pharmaceuticals

 

This is a phase I, open-label, multi-center study of IAG933 to assesss the safety and tolerability as well as anti-tumor activity in certain patient populations. This includes patients with epithelioid hemangioendothelioma (EHE).

Further information can be found on clinicaltrials.gov.

 

WHO is the trial for?
  • Adult patients with confirmed diagnosis of certain cancers incl. epithelioid hemangioendothelioma (EHE)
  • Patients must have failed available standard therapies, be intolerant or ineligible to those therapies. Or no standard therapy exists.

WHAT is the key question that this trial is attempting to answer?

 This study aims to determine the best dose of a new treatment, IAG933, and to assesss the safety and tolerability as well as anti-tumor activity in certain patient populations. This includes patients with epithelioid hemangioendothelioma (EHE).

WHY patients might want to participate?

 This clinical trial offers patients an opportunity to access a new therapy strategy. This trial will further support the research in sarcomas and potentially help other patients with this disease.

The trial might or might not have benefit in your individual case.

WHEN will the trial be open?

 The study is open for recruitment.

WHERE is the trial available?

 The trial is open in the US, Canada, Australia, France, Germany, Italy, Japan, the Netherlands, Spain, Switzerland and the UK. Please check for current information here.

STUDY DESIGN: What does the study look like?

 This study is an phase I clinical trial to test a drug called IAG933. It is divided into two parts:

  1. Dose Escalation – In this first part, researchers will gradually increase the dose of IAG933 to find the highest dose that is safe and can be tolerated by patients.
  2. Dose Expansion – Once the safe dose is determined, the second part will focus on testing the drug’s effectiveness in treating certain types of cancer and continuing to monitor its safety at the recommended dose.

The goal is to understand how well IAG933 works and how safe it is for patients.

HOW do I get more information?

 Patient organizations supporting sarcoma patients in your country may offer additional information about the trial, current recruitment status, and key contacts. Click here for a list of patient organizations serving sarcoma patients. If there are no such organization in your country, please email us for more information: info@sarcoma-patients.org

Disclaimer: This is a patient-friendly summary of the clinical trial which has been provided for informational purposes only. Patients should consult their physician about any clinical trial opportunity.

Merken